MedTrace Logo

Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer

NCT06220435 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-08-12

No results posted yet for this study

Summary

HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with node-negative high risk localized prostate cancer.

Conditions

Interventions

RADIATION

Ultra-hypofractionated radiotherapy regimen.

* Prostate tumor(s): 49 Gray (Gy)/7 fractions * Prostate gland: 42.7 Gy/7 fractions * Elective lymph nodes: 29.4 Gy/7 fractions * Seminal vesicles: 31.15 Gy/7 fractions

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Adalsteinn Gunnlaugsson, MD, PhD · Region Skåne, Lund University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-25
Primary Completion
2031-09-01
Completion
2031-09-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06220435 on ClinicalTrials.gov